Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Neoplasms of the CNS

Free Subscription Articles published in Cancer Retrieve available abstracts of 40 articles: HTML format

Single Articles

January 2026
1. ZHAO W, Li L, Fu X, Chang Y, et al
   A first-line regimen combining Bruton's tyrosine kinase and programmed cell death protein-1 inhibitors with chemotherapy excluding methotrexate achieves high response rates in primary central nervous system lymphoma.
   Cancer. 2026;132:e70247.
   PubMed     Abstract available
   
   
   December 2025
2. LAWRENCE L
   Diffuse midline gliomas get first FDA-approved drug.
   Cancer. 2025;131:e70146.
   PubMed    
   
   
   
3. 
   Correction to "Determinants of geographic variation in the incidence of adult nonmalignant meningioma in the United States, 2010-2019".
   Cancer. 2025;131:e70206.
   PubMed    
   
   
   
4. ZHANG J, Wang P, Ren Y, Chen L, et al
   Chemoradiotherapy with temozolomide vs. radiotherapy alone in patients with IDH wild-type and TERT promoter mutation histological grade 2/3 gliomas: An extension retrospective analysis of a randomized controlled trial.
   Cancer. 2025;131:e70171.
   PubMed     Abstract available
   
   
   
5. TENG H, Yu J, Pang Y, Yan O, et al
   Long-term recurrence risk and temporal dynamics after resection of intracranial meningiomas: A multicenter cohort study with up to 15 years of follow-up.
   Cancer. 2025;131:e70200.
   PubMed     Abstract available
   
   
   November 2025
6. LAWRENCE L
   ASTRO updates guideline on radiation therapy for grade 4 diffuse gliomas: After maximum safe resection, radiation therapy is the primary modality of therapy for grade 4 diffuse gliomas.
   Cancer. 2025;131:e70089.
   PubMed    
   
   
   October 2025
7. WALSH KM
   Counting what counts: Registry completeness and the epidemiology of nonmalignant meningioma.
   Cancer. 2025;131:e70100.
   PubMed    
   
   
   September 2025
8. TAN S, He H, Ni J, Guo Y, et al
   Meta-analysis evaluating the efficacy and safety of various Bruton tyrosine kinase (BTK) inhibitors for central nervous system lymphoma: Novel covalent BTK inhibitors, except for ibrutinib, also demonstrate good efficacy in the treatment of primary ce
   Cancer. 2025;131:e70083.
   PubMed     Abstract available
   
   
   
9. WITHROW DR, Boyle J, Linet MS, Pittman Ballard CA, et al
   Determinants of geographic variation in the incidence of adult nonmalignant meningioma in the United States, 2010-2019.
   Cancer. 2025;131:e70042.
   PubMed     Abstract available
   
   
   August 2025
10. PERSICO P, Dipasquale A, Losurdo A, Santoro A, et al
    Primary mismatch repair deficiency and Lynch syndrome in adult diffuse gliomas: A call to action.
    Cancer. 2025;131:e70026.
    PubMed    
    
    
    
11. RHA SY, Castanon E, Gill S, Senellart H, et al
    Lenvatinib plus pembrolizumab for patients with previously treated select solid tumors: Results from the phase 2 LEAP-005 study recurrent glioblastoma cohort.
    Cancer. 2025;131:e70015.
    PubMed     Abstract available
    
    
    
12. TANG LY, Botros D, Kim AA, Khalafallah AM, et al
    Impact of peri-tumoral resection on survival in primary glioblastoma.
    Cancer. 2025;131:e70016.
    PubMed     Abstract available
    
    
    July 2025
13. SINGH R, Roubil JG, Bowden G, Mathieu D, et al
    Clinical outcomes following stereotactic radiosurgery for brain metastases from sarcoma primaries: An international multicenter analysis.
    Cancer. 2025;131:e35931.
    PubMed     Abstract available
    
    
    June 2025
14. 
    RETRACTION: Phase 1 Study of Concurrent RMP-7 and Carboplatin with Radiotherapy for Children with Newly Diagnosed Brainstem Gliomas.
    Cancer. 2025;131:e35876.
    PubMed    
    
    
    
15. NIERENGARTEN MB
    New standard of care for patients with asymptomatic brain metastases from melanoma.
    Cancer. 2025;131:e35885.
    PubMed    
    
    
    May 2025
16. KILICKAP S, Ozguroglu M, Sezer A, Gumus M, et al
    Cemiplimab monotherapy as first-line treatment of patients with brain metastases from advanced non-small cell lung cancer with programmed cell death-ligand 1 >/=50.
    Cancer. 2025;131:e35864.
    PubMed     Abstract available
    
    
    April 2025
17. BERTUCCI A, Dufour O, Appay R, Harlay V, et al
    Characteristics, outcome, and prognostic factors of young patients with central nervous system World Health Organization grade 3 oligodendrogliomas IDH-mutant and 1p/19q codeleted: A French POLA network study.
    Cancer. 2025;131:e35814.
    PubMed     Abstract available
    
    
    March 2025
18. CANNATARO VL, Bracci PM, Taylor JW, McCoy L, et al
    Glioma mutational signatures associated with haloalkane exposure are enriched in firefighters.
    Cancer. 2025;131:e35732.
    PubMed     Abstract available
    
    
    November 2024
19. SINGER S, Schranz M, Hippler M, Kuchen R, et al
    Frequency and clinical associations of common mental disorders in adults with high-grade glioma-A multicenter study.
    Cancer. 2024 Nov 17. doi: 10.1002/cncr.35653.
    PubMed     Abstract available
    
    
    
20. CHAI TS, Rodgers-Fouche LH, Walls JO, Mattia AR, et al
    Real-world genetic testing outcomes of pan-cancer testing for mismatch repair deficiency.
    Cancer. 2024;130:3888-3893.
    PubMed     Abstract available
    
    
    October 2024
21. AHMAD S, Muhlebner A, Snijders TJ, de Leng WW, et al
    Somatostatin receptor 2A expression in von Hippel-Lindau-related hemangioblastomas.
    Cancer. 2024;130:3473-3479.
    PubMed     Abstract available
    
    
    July 2024
22. ASFAW ZK, Hernandez-Marquez GC, Germano IM
    Patients with glioblastoma: A tale of health care access and genetic ancestry.
    Cancer. 2024 Jul 8. doi: 10.1002/cncr.35470.
    PubMed    
    
    
    May 2024
23. HSIEH AL, Bi WL, Ramesh V, Brastianos PK, et al
    Evolving concepts in meningioma management in the era of genomics.
    Cancer. 2024 May 16. doi: 10.1002/cncr.35279.
    PubMed     Abstract available
    
    
    February 2024
24. ZHOU Y, Guo T, Liang F, Wang Z, et al
    Cumulative incidence and risk factors of brain metastases in metastatic non-small cell lung cancer without baseline brain metastasis: Pooled analysis of individualized patient data from IMpower130, IMpower131, and IMpower150.
    Cancer. 2024 Feb 14. doi: 10.1002/cncr.35242.
    PubMed     Abstract available
    
    
    January 2024
25. RANJAN S, Leung D, Ghiaseddin AP, Taylor JW, et al
    Practical guidance for direct oral anticoagulant use in the treatment of venous thromboembolism in primary and metastatic brain tumor patients.
    Cancer. 2024 Jan 30. doi: 10.1002/cncr.35220.
    PubMed     Abstract available
    
    
    
26. VAN NOT OJ, van den Eertwegh AJM, Haanen JB, van Rijn RS, et al
    BRAF/MEK inhibitor rechallenge in advanced melanoma patients.
    Cancer. 2024 Jan 10. doi: 10.1002/cncr.35178.
    PubMed     Abstract available
    
    
    October 2023
27. LI Y, Cao J, Wang J, Wu W, et al
    Association of the m(6) A reader IGF2BP3 with tumor progression and brain-specific metastasis in breast cancer.
    Cancer. 2023 Oct 20. doi: 10.1002/cncr.35048.
    PubMed     Abstract available
    
    
    
28. PAPINI C, Willard VW, Gajjar A, Merchant TE, et al
    Social cognition and adjustment in adult survivors of pediatric central nervous system tumors.
    Cancer. 2023;129:3064-3075.
    PubMed     Abstract available
    
    
    September 2023
29. RIEDINGER CJ, Esnakula A, Haight PJ, Suarez AA, et al
    Characterization of mismatch-repair (MMR)/microsatellite instability (MSI)-discordant endometrial cancers.
    Cancer. 2023 Sep 26. doi: 10.1002/cncr.35030.
    PubMed     Abstract available
    
    
    
30. LU S, Guo X, Li Y, Liu H, et al
    Antiprogrammed death ligand 1 therapy failed to reduce the risk of developing brain metastases in patients with extensive-stage small cell lung cancer: A retrospective analysis.
    Cancer. 2023 Sep 8. doi: 10.1002/cncr.35003.
    PubMed     Abstract available
    
    
    August 2023
31. HEFFERNAN AE, Wu Y, Benz LS, Verhaak RGW, et al
    Quality of life after surgery for lower grade gliomas.
    Cancer. 2023 Aug 20. doi: 10.1002/cncr.34980.
    PubMed     Abstract available
    
    
    
32. MAAS A, Maurice-Stam H, Kremer LCM, van der Aa-van Delden A, et al
    Psychosocial outcomes in long-term Dutch adult survivors of childhood cancer: The DCCSS-LATER 2 psycho-oncology study.
    Cancer. 2023;129:2553-2567.
    PubMed     Abstract available
    
    
    
33. BAIREY O, Taliansky A, Glik A, Amiel A, et al
    A phase 2 study of ibrutinib maintenance following first-line high-dose methotrexate-based chemotherapy for elderly patients with primary central nervous system lymphoma.
    Cancer. 2023 Aug 12. doi: 10.1002/cncr.34985.
    PubMed     Abstract available
    
    
    June 2023
34. BALIGA S, Palmer JD, Yock TI
    Reply to "Is the hippocampus-sparing attempt really reasonable within the current technological possibilities?".
    Cancer. 2023;129:1779-1780.
    PubMed    
    
    
    
35. ELMALI A, Mohammadipour S, Yazici G
    Is the hippocampus-sparing attempt really reasonable within the current technological possibilities?
    Cancer. 2023;129:1777-1778.
    PubMed    
    
    
    May 2023
36. MULLER BARK J, Trevisan Franca de Lima L, Zhang X, Broszczak D, et al
    Proteome profiling of salivary small extracellular vesicles in glioblastoma patients.
    Cancer. 2023 May 31. doi: 10.1002/cncr.34888.
    PubMed     Abstract available
    
    
    
37. ESTEVEZ-ORDONEZ D, Abdelrashid M, Coffee E, Laskay NMB, et al
    Racial and socioeconomic disparities in glioblastoma outcomes: A single-center, retrospective cohort study.
    Cancer. 2023 May 28. doi: 10.1002/cncr.34881.
    PubMed     Abstract available
    
    
    
38. NEFF C, Price M, Cioffi G, Kruchko C, et al
    Complete prevalence of primary malignant and non-malignant brain tumors in comparison to other cancers in the United States.
    Cancer. 2023 May 18. doi: 10.1002/cncr.34837.
    PubMed     Abstract available
    
    
    
39. BARDEN MM, Omuro AM
    Top advances of the year: Neuro-oncology.
    Cancer. 2023;129:1467-1472.
    PubMed     Abstract available
    
    
    April 2023
40. COLE KA, Ijaz H, Surrey LF, Santi M, et al
    Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcoma.
    Cancer. 2023 Apr 20. doi: 10.1002/cncr.34786.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Neoplasms of the CNS is free of charge.